Mangalam Drugs & Organics bulk deal: Vijay Kedia sells 1.38 lakh shares worth Rs 48 lakh
https://img.etimg.com/thumb/msid-126398210,width-1200,height-630,imgsize-1179024,overlay-etmarkets/articleshow.jpg
The other sellers included Neo Apex Venture LLP (Rs 27.6 lakh), Epitome Trading and Investments (Rs 42 lakh) and Multiplier Share & Stock Advisors Private Limited (Rs 44 lakh).
Shares of Mangalam Drugs surged 5% today to settle at Rs 35.18 on the NSE.
Also Read: Ashish Kacholia picks up 2.9% stake in smallcap Adcounty Media. Stock down 60% from peak
Mangalam Drugs, a Gujarat-based company, commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates in 1977. It has a multi-product manufacturing facility on two locations, and an in-house Research & Development laboratory.
The share price of Mangalam Drugs has eroded by 69% in the past 12 months. But the stock has seen significant buying action over the past month with shares jumping nearly 40%.
Despite the late rally, the company’s shares are trading below their 50-day and 200-day simple moving averages (SMAs) of Rs 39.6 and Rs 69.3, respectively, according to Trendlyne data.Also Read: Ramkrishna Forgings bulk deal: Morgan Stanley buys shares worth Rs 95 crore
The rally has pushed the counter into a strongly overbought zone with Day’s MFI suggesting a level around 90. A number above 70 is considered as overbought while below 30 is viewed as oversold.
The company reported a consolidated net loss of Rs 7.4 crore in the quarter-ended September 30, 2025 compared to a profit after tax (PAT) of Rs 2.7 crore in the year ago period. The total revenue in the quarter under review was reported at Rs 50 crore, down 38% from Rs 80 crore posted by the company in the corresponding quarter of the last financial year.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
Post Comment